Sanofi Confirms its Decades-Long Commitment to the Fight against Malaria
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) confirmed its decades-long commitment to the fight against malaria at the opening of 10th Edition of the Pan-African Conference against Malaria.
AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures
- Details
- Category: AstraZeneca
AstraZeneca has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million.
Pradaxa® awarded Prix Galien for most innovative product in Canada
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim's breakthrough novel oral anticoagulant Pradaxa® (dabigatran etexilate) was awarded the prestigious Prix Galien in Canada. At a Gala Ceremony during the Tenth Annual Canadian Health Research Awards Ceremony in Ottawa, Pradaxa® (Pradax® in Canada) was recognised as the most innovative Canadian product in 2011.
Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is providing more than $4 million in additional funding to the Infectious Disease Research Institute. The funding will allow IDRI to continue its early phase drug discovery efforts focused on identifying new and better therapies in the fight against tuberculosis,
Merck Sends Assistance to Flood-Ravaged Thailand
- Details
- Category: Merck Group
Merck KGaA and its Life Science division Merck Millipore have sent thousands of state-of-the-art water test kits to Thailand in an effort to ensure the safety of municipal drinking water following months of devastating flooding in that region.
Pfizer to Acquire Excaliard Pharmaceuticals
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.
Enbrel® (etanercept) Patent Issued
- Details
- Category: Amgen
Amgen announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc. ("Roche") and exclusively licensed to Amgen.
More Pharma News ...
- FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
- Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program
- Novartis and collaborators discover new dual-acting class of antimalarial compounds
- Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration
- Bayer plans further expansion in Asia
- SATURN demonstrated effect of intensive statin treatment on reducing atherosclerosis
- Bristol-Myers Squibb Foundation's Together on Diabetes® Initiative Marks First Anniversary